Leerink initiated coverage of Neogenomics (NASDAQ:NEO) with an “outperform” rating and price target of $18. The stock closed at $12.84 on August 20. Analyst Puneet Souda writes that Neogenomics is a “uniquely positioned...

Roth Capital Partners downgraded Lannett Co. (NYSE AMER:LCI) to “neutral” and slashed its price target to $8 from $23 after the company lost an important customer and issued a profit warning. Near midday on August 20...

Needham initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and $30 price target. The stock closed at $14.90 on August 17. Liquidia is developing LIQ861, a differentiated inhaled treatment for...

Ladenburg Thalmann initiated coverage of Achieve Life Sciences (NASDAQ:ACHV) with a “buy” rating and $12 price target. The stock finished at $2.80 on August 17. Achieve is developing cytisine, a natural compound with...

Ladenburg Thalmann launched coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and price target of $7. The stock closed at $2.95 on August 15. AcelRx is focused on the development of acute pain...

Maxim Group downgraded Cytori Therapeutics (NASDAQ:CYTX) to “hold” from “buy” and removed its price target, citing capital concerns. The stock closed at 40 cents on August 14. “Our fundamental view around the...

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

H.C. Wainwright upgraded Dicerna Pharmaceuticals (NASDAQ:DRNA) to “buy” from “neutral” and raised its price target to $21 from $14, citing broad progress across the company’s pipeline. The stock closed at $14.82 on...

JP Morgan upgraded Idera Pharmaceuticals (NASDAQ:IDRA) to “overweight” with a December 2019 price target of $15, following a period of restriction and a “not-rated” designation. JP Morgan had rated the stock, which...

Analysts for Leerink and JP Morgan initiated coverage for Replimune (NASDAQ:REPL) with “outperform” and “overweight” ratings, respectively. Leerink set its price target at $25 and JP Morgan at $26 for December 2019...

Mackie Research downgraded Correvio Pharma (NASDAQ:CORV) to “hold” from “speculative buy” but raised its price target to $4.70 from $3.30, citing the stock’s run up after a positive FDA announcement on the company’s...

Roth Capital Partners downgraded Gemphire Therapeutics (NASDAQ:GEMP) to “neutral” from “buy” with a $2 price target after the company terminated its Phase 2a pediatric non-alcoholic fatty liver disease (NAFLD) trial...

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

JP Morgan initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with an “overweight” rating and $17 December 2019 price target. The stock closed at $9.85 on August 10. Analyst Anupam Rama writes that using...

Leerink launched coverage of Crinetics Pharma (NASDAQ:CRNX) with an “outperform” rating and a $43 price target. The stock closed at $30.68 on August 10. Crinetics is building a rare disease franchise in endocrinology...

Piper Jaffray downgraded Endologix (NASDAQ:ELGX) to “neutral” from “overweight” and lowered its price target to $4.75 from $7 after the company meaningfully reduced revenue guidance for the year as it moves to revamp...

Maxim Group hiked its price target for BioLife Solutions (NASDAQ:BLFS) to $26 from $18 as the company in the second quarter reported a net profit for the first time since inception. The stock was quoted at $19.68 in...

Ladenburg Thalmann downgraded Neovasc (NASDAQ:NVCN) to “neutral” from “buy” and slashed its price target to 8 cents from $1, reflecting reduced revenue projections coupled with a greatly increased number of shares...

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

William Blair upgraded Vital Therapies (NASDAQ:VTL) to “outperform” from “market perform” and raised its fair value estimate to $35 from $10 ahead of top-line data from a pivotal study expected in September. The stock...

BTIG raised its price target for ViewRay (NASDAQ:VRAY) to $14 from $10 after the stock pulled back from a recent climb to nearly $13. It closed at $11.05 on Aug. 3. “We felt the stock had overrun a bit to near $13 and...